

Emilie JOUANJUS - Publications 2015-2019

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Equipe émergente : Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales

Mise à jour juillet 2019

2019

1. Auffret M, Rolland B, Béhal H, Labreuche J, **Jouanjus E**, Bordet R, Gautier S. [A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France](#). *Thérapie*. 2019 Jun 20. pii: S0040-5957(19)30099-X. doi: 10.1016/j.therap.2019.06.002. [Epub ahead of print]
2. **Jouanjus E**, Micallef J, Mallaret M, Lapeyre-Mestre M; French Addictovigilance Network. [Generalizing the use of a multidimensional approach to move towards an effective Addictovigilance](#). *Int J Neuropsychopharmacol*. 2019 Jun 13. pii: pyz033. doi: 10.1093/ijnp/pyz033. [Epub ahead of print]
3. Coutens B, Mouldous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin A, Guiard BP, **Jouanjus E**. [Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse](#). *Psychopharmacology (Berl)*. 2019 Mar 16. doi: 10.1007/s00213-019-05198-z. [Epub ahead of print]
4. Driot D, **Jouanjus E**, Oustric S, Dupouy J, Lapeyre-Mestre M. [Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France](#). *Br J Clin Pharmacol*. 2019 Jun;85(6):1260-1269. doi: 10.1111/bcp.13892.

2018

1. Gentile G, Jegou M, Spadari M, Griffiths K, **Jouanjus E**, Micallef J. [Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?](#) *Fundam Clin Pharmacol*. 2018 Dec;32(6):643-651. doi: 10.1111/fcp.12401.
2. **Jouanjus E**, Goyal H. [Cardiovascular complications of cannabis use](#). *Trends Cardiovasc Med*. 2018 Dec 10. pii: S1050-1738(18)30261-5. doi: 10.1016/j.tcm.2018.12.002. [Epub ahead of print]
3. **Jouanjus E**, Guerne G, Lapeyre-Mestre M; French Addictovigilance Network. [Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion](#). *Fundam Clin Pharmacol*. 2018 Jun;32(3):306-322. doi: 10.1111/fcp.12356.
4. Lafaurie M, Pochard L, Lotiron C, Molinier L, Lapeyre-Mestre M, **Jouanjus E**. [Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital](#). *Clin Drug Investig*. 2018 Oct;38(10):977-982. doi: 10.1007/s40261-018-0679-4.
5. Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, **Jouanjus E**, Lapeyre-Mestre M, Durrieu G, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting](#). *Drug Saf*. 2018 May;41(5):511-514. doi: 10.1007/s40264-017-0630-2.

6. Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, **Jouanjus E**, Lapeyre-Mestre M, Durrieu G, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting](#). Drug Saf. 2018 May;41(5):511-514. doi: 10.1007/s40264-017-0630-2.

2017

7. Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, Gibaja V, Caous AS, Eiden C, Authier N, Le Boisselier R, Guerlais M, **Jouanjus E**, Lepelley M, Pizzoglio V, Pain S, Richard N, Micallef J; le Réseau français d'addictovigilance. [\[Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network\]](#). Therapie. 2017 Feb 22. pii: S0040-5957(17)30042-2. doi: 10.1016/j.therap.2017.01.010.
8. **Jouanjus E**, Mallaret M, Micallef J, Ponté C, Roussin A, Lapeyre-Mestre M. [Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter"](#). Drug Saf. 2017 Feb;40(2):183-185. doi: 10.1007/s40264-016-0497-7.
9. **Jouanjus E**, Raymond V, Lapeyre-Mestre M, Wolff V. [What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review](#). Curr Atheroscler Rep. 2017 Jun;19(6):26. doi: 10.1007/s11883-017-0663-0.
10. Ponté C, Pi C, Palmaro A, **Jouanjus E**, Lapeyre-Mestre M; French Addictovigilance Network. [Early signal of diverted use of tropicamide eye drops in France](#). Br J Clin Pharmacol. 2017 Aug;83(8):1791-1800. doi: 10.1111/bcp.13272.
11. Wolff V, **Jouanjus E**. [Strokes are possible complications of cannabinoids use](#). Epilepsy Behav. 2017 May;70(Pt B):355-363. doi: 10.1016/j.yebeh.2017.01.031.

2016

1. Driot D, Chicoulaa B, **Jouanjus E**, Dupouy J, Oustric S, Lapeyre-Mestre M. [Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history](#). Therapie. 2016 Dec;71(6):575-578. doi: 10.1016/j.therap.2016.04.006.
2. Eiden C, Nogue E, Diot C, Frauger E, **Jouanjus E**, Léglièze Y, Picot MC, Peyriere H. [Three Complementary Approaches to Characterize Buprenorphine Misuse](#). Subst Use Misuse. 2016 Dec 5;51(14):1912-9. doi: 10.1080/10826084.2016.1201509.
3. Bossard JB, Ponté C, Dupouy J, Lapeyre-Mestre M, **Jouanjus E**. [Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database](#). Clin Drug Investig. 2016 Sep;36(9):735-42. doi: 10.1007/s40261-016-0421-z.

2015

1. **Jouanjus E**, Gibaja V, Kahn JP, Haramburu F, Daveluy A. [Signal identification in addictovigilance: the functioning of the French system](#). Therapie. 2015 Mar-Apr;70(2):113-31. doi: 10.2515/therapie/2015011. English, French.
2. Pauly V, Lapeyre-Mestre M, Braunstein D, Rueter M, Thirion X, **Jouanjus E**, Micallef J. [Detection of signals of abuse and dependence applying disproportionality analysis](#). Eur J Clin Pharmacol. 2015 Feb;71(2):229-36. doi: 10.1007/s00228-014-1783-x.